CasLoc logo
All Cases PTAB Litigations UPC Oppositions

Astellas US LLC v. Fresenius Kabi USA LLC

1:12-cv-01699

Overview

Case Number 1:12-cv-01699
Filing Date 2012-12-12
Status Terminated
Termination Date 2013-03-27
Court District Court, D. Delaware (ded)
Nature of Suit 830 Patent
Jurisdiction Type Federal Question
Cause of Action 35:271 Patent Infringement
Jury Demand None

Parties

Defendant

Fresenius Kabi USA LLC Operating Company

Represented By

2 Attorneys Listed

Megan C. Haney

Phillips, Goldman, McLaughlin & Hall, P.A.

Tel: +1 (302) 655-4200

Phillips, Goldman, McLaughlin & Hall, P.A., 1200 North Broom Street

John C. Phillips , Jr.

Phillips, McLaughlin & Hall, P.A.

Tel: +1 (302) 655-4200

Phillips, McLaughlin & Hall, P.A., 1200 N. Broom St

Plaintiff

Item Development AB NPE (Individual / Inventor)

Represented By

2 Attorneys Listed

Maryellen Noreika

Morris, Nichols, Arsht & Tunnell LLP

Tel: +1 (302) 658-9200

1201 North Market Street, P.O. Box 1347

Jack B. Blumenfeld

Morris, Nichols, Arsht & Tunnell LLP

Tel: +1 (302) 658-9200

1201 North Market Street, P.O. Box 1347

Astellas Pharma US, Inc. Operating Company

Represented By

2 Attorneys Listed

Maryellen Noreika

Morris, Nichols, Arsht & Tunnell LLP

Tel: +1 (302) 658-9200

1201 North Market Street, P.O. Box 1347

Jack B. Blumenfeld

Morris, Nichols, Arsht & Tunnell LLP

Tel: +1 (302) 658-9200

1201 North Market Street, P.O. Box 1347

Astellas US LLC Operating Company

Represented By

2 Attorneys Listed

Maryellen Noreika

Morris, Nichols, Arsht & Tunnell LLP

Tel: +1 (302) 658-9200

1201 North Market Street, P.O. Box 1347

Jack B. Blumenfeld

Morris, Nichols, Arsht & Tunnell LLP

Tel: +1 (302) 658-9200

1201 North Market Street, P.O. Box 1347

Court & Judges

Court

District Court, D. Delaware (ded)

Global Patent Family Cross-Litigation Radar

CasLoc 360Β° Radar 8 Family Members

Multi-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions

πŸ‡ΊπŸ‡Έ
U.S. District Courts 3 proceedings
πŸ›οΈ
USPTO PTAB Trials Counterparts in force
πŸ‡ͺπŸ‡Ί
Unified Patent Court (UPC) Counterparts in force
πŸ‡©πŸ‡ͺ
European Patent Office (EPO) Counterparts in force
Worldwide Family Members (8): πŸ‡ΊπŸ‡Έ US
Parallel Proceedings Across Jurisdictions (3 found):
U.S. Courts: 3
U.S. District Court 2012-11-19
1:12-cv-01489

Astellas US LLC v. Akorn Inc.

Asserted Patent
Status: DED
U.S. District Court 2012-05-23
1:12-cv-00652

Astellas US LLC v. Hospira Inc.

Asserted Patent
Status: DED
U.S. District Court 2005-05-26
1:05-cv-00337

King Pharmaceuticals Research and Development, Inc. v. SICOR Inc.

Asserted Patent
Status: DED
Stay ahead of cross-border rulings. Subscribe for free automated docket alerts across U.S. Courts, PTAB, UPC, and EPO.

Patents Involved

1 Patent

There is a single patent involved in this case.

Patent Asset Filing & Issue Date Expiration & Term Status External Links
US5731296
Selective vasodilation by continuous adenosine infusion
Filed: 1993-03-15
Issued: 1998-03-24
Expired (Term Ended)
Expires: 2013-03-15

Patent Enforceability & Injunction Risk Assessment

Statutory Analysis
Injunction Viability (35 U.S.C. Β§ 283) Statutorily Barred

Statutorily Barred β€” Patent expired. Under 35 U.S.C. Β§ 283, injunctive relief is barred.

Terminal Disclaimer & Cellect Risk Low Risk

Standard Statutory Term β€” No obviousness-type double patenting noted.

Damages Lookback Horizon 6-Yr Max Lookback

Under 35 U.S.C. Β§ 286, damages cannot accrue for infringement prior to 6 years before filing. All Statutory Maintenance Fees Paid (12-Year Window Cleared).

Docket Entries

(15 total)
Pleading / Complaint

COMPLAINT FOR PATENT INFRINGEMENT - filed against Fresenius Kabi USA LLC - Magistrate Consent Notice to Pltf. ( Filing fee $ 350.00, receipt number 0311-1189727.) - filed by Astellas US LLC, Astellas Pharma US, Inc., Item Development AB. (Attachments: # 1 Exhibit A, # 2 Civil Cover Sheet)(rwc) (Entered: 12/13/2012)

Entry #1 • 2012-12-12
1

Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (rwc) (Entered: 12/13/2012)

Entry #2 • 2012-12-12
1

Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 11/1/12. Date of Expiration of Patent: 3/24/15.Thirty Month Stay Deadline: 4/30/2015. (rwc) (Entered: 12/13/2012)

Entry #3 • 2012-12-12
1

Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 5,731,296. (rwc) (Entered: 12/13/2012)

Entry #4 • 2012-12-12
1

Disclosure Statement pursuant to Rule 7.1 filed by Astellas Pharma US, Inc., Astellas US LLC identifying Corporate Parent Astellas US Holding Inc., Corporate Parent for Astellas Pharma US, Inc., Astellas US LLC. (rwc) (Entered: 12/13/2012)

Entry #5 • 2012-12-12
1

Track Case Updates

Automated email notifications for new filings & decisions

Identifier: •

Free service • 1-click unsubscribe anytime • Powered by CasLoc